Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 2, 2018, Pages

  Bergman, Hanna ^a   Rathbone, John ^b   Agarwal, Vivek ^c   Soares Weiser, Karla ^a  

^a Cochrane Response ^*  (United Kingdom)

^b BOND UNIVERSITY   (Australia)

^c The Lakes Mental Health Unit ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TETRABENAZINE; THIOPROPAZATE; ZIPRASIDONE; ZUCLOPENTHIXOL;

AKATHISIA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSTONIA; FOLLOW UP; HUMAN; MENTAL DISEASE; MENTAL HEALTH; META ANALYSIS; OUTCOME ASSESSMENT; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG SUBSTITUTION; DYSKINESIA; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT WITHDRAWAL;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; WITHHOLDING TREATMENT;

EID: 85041637656     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000459.pub3     Document Type: Review

References (288)

1. Bai YM, Lin CC, Yu SC. Risperidone for severe tardive dyskinesia: one year follow up study. International Journal of Neuropsychopharmacology 2002;5:S165. 7476419
2. Bai YM, Yu SC, Chen JY, Lin CY, Chou P, Lin CC. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. International Clinical Psychopharmacology 2005;20(2):79-85. 7476420
3. Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2003;64:1342-8. 7476421
4. Pai YM, Yu SC, Lin CC. Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. 7476422
5. Pai YM, Yu SC, Lin CC. Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. 2001. 7476423
6. Bai YM. Tardive dyskinesia and cognitive function. clinicaltrials.gov/ct2/show/record/NCT00926965 accessed on 20 June 2016. 7476427
7. Bai YM, Ping LY, Lin CC, Wang YC, Liou YJ, Wu BJ, et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study. 8th World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt. 2005. 7476426
8. Bai YM, Ping LY, Lin CC, Wang YC, Liou YJ, Wu BJ, et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study. European Neuropsychopharmacology 2005;15(Suppl 3):S473. 7476425
9. CaroffSN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry 2011;72(3):295-303. [DOI: 10.4088/JCP.09m05793yel]7476429
10. Miller DD, CaroffSN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. British Journal of Psychiatry 2008; Vol. 193, issue 4:279-88. 7476430
11. Miller DD, McEvoy JP, Davis SM, CaroffSN, Saltz BL, Chakos MH, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research 2005; Vol. 80, issue 1:33-43. 7476431
12. Chan HY, Chiang SC, Chang CJ, Gau SS, Chen JJ, Chen CH, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. Journal of Clinical Psychiatry 2010;71(9):1226-33. 7476433
13. NCT00621998. Risperidone and olanzapine for the schizophrenic patients with neuroleptic-induced tardive dyskinesia. www.clinicaltrials.gov 2008. 7476434
14. Chouinard G, Arnott W. An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6-12:22. 7476436
15. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology 1993;13(1):25-40. 7476437
16. Chouinard, G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology 1995;15(Suppl 1):S36-S44. 7476440
17. Chouinard, G. Arnott W. Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology 1992;15 (Suppl 1 Pt B):266. 7476438
18. Chouinard, G. Arnott W. The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry 1992;31:158. 7476439
19. Cookson IB. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology 1987;2:141-9. 7476442
20. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry 2004;65(5):696-701. [MEDLINE: 15163258]7476444
21. Emsley RA, Turner J, Schronen J, Botha K, Smit R, Oosthuizen PP. Quetiapine: greater improvements in tardive dyskinesia versus haloperidol. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA. 2004. [APA Conference Abstracts NR574]7476445
22. Glazer WM, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research 1990;3(5-6):315-20. [MEDLINE: 91129137; PMID 1980827]7476447
23. Glazer WM, Hafez HM, Benarroche CL. Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry 1985;46(8):4-7. [MEDLINE: 91129137; PMID 1980827]7476448
24. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantokos S, Schiebel D, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry 1983;40(8):893-6. 7476450
25. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Archives of General Psychiatry 1972;27(1):100-3. 7476452
26. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry 1973;130(4):479-83. 7476454
27. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology 1991;1(4):541-8. 7476456
28. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry 1994;55(9, Suppl B):102-6. 7476458
29. Albus M, Naber D, Muller-Spahn F, Douillet P, Reinertshofer T, Ackenheil M. Tardive dyskinesia: relation to computer-tomographic, endocrine, and psychopatholgical variables. Biological Psychiatry 1985;20:1082-9. 7476460
30. Ananth JV, Ban TA, Lehmann HE. An uncontrolled study with thiopropazate in the treatment of persistent dyskinesia. Psychopharmacology Bulletin 1977;13(3):9. 7476462
31. Andersson U, Haggstrom JE, Nilsson MJ, Widerlov E. Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia. Psychopharmacology 1988;94(2):167-71. 7476464
32. Andia I, Zumarraga M, Zabalo MJ, Bulbena A, Davila R. Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia. Biological Psychiatry 1998;43:20-3. 7476466
33. Asnis GM, Sachar EJ, Langer G, Halpern FS, Fink M. Normal prolactin responses in tardive dyskinesia. Psychopharmacology 1979;66(3):247-50. 7476468
34. Auberger S, Greil W, Ruther E. Tiapride in the treatment of tardive dyskinesia. A double-blind study. Pharmacopsychiatry 1985;18(1):61-2. [EMBASE 1998088014]7476470
35. Barnes T. A prospective study of tardive dyskinesia in the elderly; single-blind comparison of amisulpride and risperidone. National Research Register 2002. [N0195113456]7476472
36. Bateman DN, Dutta DK, McClelland HA, Rawlins MD. The effect of metoclopramide and haloperidol on tardive dyskinesia. British Journal of Pharmacology 1979;66(3):475-6. 7476474
37. Bitter I, Slabber M, Pretorius J, Bartko GY, Danics Z, Dossenbach M, et al. Olanzapine versus clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S141. 7476476
38. Blaha L. A strategy to reduce the frequency of early dyskinesias under high-dosed haloperidol treatment [Therapiekonzept zur reduktion der fruehdyskinesie-frequenz bei hochdosierter haloperidolbehandlung]. Arzneimittel Forschung 1980;30(8):1208. [N0195113456]7476478
39. Borison RL, Shah C, White TH, Diamond BI. Atypical and typical neuroleptics and tardive dyskinesia. Psychopharmacology Bulletin 1987;23(1):218-20. 7476480
40. Branchey MH, Branchey LB, Richardson MA. Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia. Psychopharmacology Bulletin 1981;17(1):118-20. 7476482
41. Branchey MH, Branchey LB, Richardson MA. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. American Journal of Psychiatry 1981;138(5):608-12. 7476483
42. Brecher M. Follow-up study of risperidone in the treatment of patients with dementia: interim results on tardive dyskinesia and dyskinesia severity. 11th European College of Neuropsychopharmacology Congress (ECNP). Paris: European College of Neuropsychopharmacology, 1998 Oct 31-Nov 4, Paris:P4005. 7476487
43. Brecher M, Okamoto A, Napolitano J, Kane JM, The Risperidone Study Group. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year. Schizophrenia Research 1999;1-3:362. 7476485
44. Brecher M, Okamoto A, Napolitano J, Kane JM, Risperidone Study Group. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year. American Journal of Geriatric Psychiatry 1999;7:53-4. 7476486
45. Buchanan RW, Kirkpatrick B, Summerfelt A, Hanlon TE, Levine J, Carpenter TW Jr. Clinical predictors of relapse following neuroleptic withdrawal. Biological Psychiatry 1992;32:72-8. 7476489
46. Burner M, Giroux C, L'Heritier C, Garreau M, Morselli PL. Preliminary observations on the therapeutic action of progabide in tardive dyskinesia. Brain Dysfunction 1989;2(6):289-96. [MEDLINE: 87273387; PMID 2886223]7476491
47. Buruma OJ, Roos RA, Bruyn GW, Kemp B, Van der Velde EA. Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica 1982;65(1):38-44. [MEDLINE: 82155989; PMID 6121443]7476493
48. Cai N. A controlled study on the treatment of tardive dyskinesia using 1-stepholidine. Chinese Journal of Neurology and Psychiatry 1988;21(5):281-3. 7476495
49. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. American Journal of Psychiatry 1979;136:317-20. 7476497
50. Calne DB, Claveria LE, Teychenne PF, Haskayne L, Lodge-Patch IC. Pimozide in tardive dyskinesia. Transcripts of the American Neurology Association 1974;99:166-70. 7476499
51. Armenteros JL, Adams PB, Campbell M, Eisenberg ZW. Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. Psychopharmacology Bulletin 1995;31(2):363-9. 7476501
52. Campbell M, Adams P, Perry R, Spencer EK, Overall JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacology Bulletin 1988;24(2):251-5. 7476502
53. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective longitudinal study. Journal of the American Acadamy of Child and Adolescent Psychiatry 1997;36(6):835-43. 7476503
54. Carpenter WT, Rey AC, Stephens JH. Covert dyskinesia in ambulatory schizophrenia. The Lancet 1980;July:212-3. 7476505
55. Casey DE, Denney D. Pharmacological characterization of tardive dyskinesia. Psychopharmacology Berlin 1977;54(1):1-8. 7476507
56. Casey DE, Gerlach J, Simmelsgaard H. Sulpiride in tardive dyskinesia. Psychopharmacology 1979;66:73-7. [N0195113456]7476509
57. Casey DE, Korsgaard S, Gerlach J, Jorgensen A, Simmelsgaard H. Effect of des-tyrosine-gamma-endorphin in tardive dyskinesia. Archives of General Psychiatry 1981;38(2):158-60. 7476511
58. Casey DE. Tardive dyskinesia: what is the natural history?. International Drug Therapy Newsletter 1983;18:13-6. 7476513
59. Cassady SL, Thaker GK, Moran M, Birt A, Tamminga CA. GABA agonist-induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia. Biological Psychiatry 1992;32(4):302-11. 7476515
60. Chouinard G, Annable L, Kropsky M. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Pharmacology 1978;18(2-3):148-54. 7476517
61. Chouinard G, Annable L, Ross-Chouinard A, Kropsky ML. Ethopropazine and benztropine in neuroleptic-induced parkinsonism. Journal of Clinical Psychiatry 1979;40(3):147-52. 7476519
62. Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Journal of Clinical Psychopharmacology 1989;9(4):247-53. 7476521
63. Chouinard G, Vainer JL, Belanger MC, Turnier L, Beaudry P, Roy JY, et al. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Progress in Neuro-psychopharmacology & Biological Psychiatry 1994;18(7):1129-41. 7476523
64. Claveria LE, Teychenne PF, Calne DB, Haskayne L, Petrie A, Pallis CA, et al. Tardive dyskinesia treated with pimozide. Journal of the Neurological Sciences 1975;24(4):393-401. 7476525
65. Cookson JC. Side effects during long-term treatment with depot antipsychotic medication. Clinical Neuropharmacology 1991;14(Suppl 2):S24-32. 7476527
66. Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, et al. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. Journal of Clinical Psychopharmacology 2008;28(1):69-73. 7476529
67. Cowen MA, Green M, Bertollo DN, Abbott K. A treatment for tardive dyskinesia and some other extrapyramidal symptoms. Journal of Clinical Psychopharmacology 1997;17(3):190-3. 7476531
68. Crane GE. Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie 1968;9(2):209-16. 7476533
69. Crane GE, Ruiz P, Kernohan J, Wilson W, Royalty N. Effects of drug withdrawal on tardive dyskinesia. Activitas Nervosa Superior 1969;11:30-5. 7476535
70. Crane GH. High doses of trifluperazine and tardive dyskinesia. Archives of Neurology 1970;22(2):176-80. 7476537
71. Curran JP. Management of tardive dyskinesia with thiopropazate. American Journal of Psychiatry 1973;130:925-7. 7476539
72. Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long term depot maintenance of chronic schizophrenic out patients: the seven year follow up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side effects, neurotic symptoms and depression. British Journal of Psychiatry 1985;146:469-74. 7476541
73. Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. International Journal of Geriatric Psychiatry 2000;15(6):506-14. 7476543
74. de Jesus Mari J, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, de Oliveira IR, et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. European Archives of Psychiatry and Clinical Neuroscience 2004;254(6):356-61. [DOI: 10.1007/s00406-004-0514-1]7476545
75. Delwaide PJ, Desseilles M. Controlled therapeutic study of spontaneous bucco-linguo-facial dyskinesias [Etude therapeutique controlee des dyskinesies bucco-linguo-faciales spontanees]. Semaine des Hopitaux 1979;55(35-6):1585-9. [MEDLINE: 97392141; PMID 9248874]7476547
76. Diamond BI, Borison RL. Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia. Psychopharmacology Bulletin 1986;22(3):900-5. 7476549
77. Dixon L, Thaker G, Conley R, Ross D, Cascella N, Tamminga C. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophrenia Research 1993;10(3):267-71. 7476551
78. Fahn S. Long term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents. Advances in Neurology 1983;37:267-76. 7476553
79. Fahn S. A therapeutic approach to tardive dyskinesia. Journal of Clinical Psychiatry 1985;46:19-24. 7476555
80. Freeman H, Soni SD. Oxypertine for tardive dyskinesia. British Journal of Psychiatry 1980;136:522-3. [MEDLINE: 80221656; PMID 6104524]7476557
81. Freeman HL, Soni SD. Treatment of tardive dyskinesia with oxypertine. Supplement to Progress in Neuropsychopharmacology. Proceedings of the 12th Congress of Collegium Internationale Neuro-psychopharmacologicum; 1980. 1980. [MEDLINE: 77131327; PMID 1020682]7476559
82. Freeman HL, Soni SD, Carpenter L. A controlled trial of oxypertine in tardive dyskinesia. International Pharmacopsychiatry 1980;15(5):281-91. [MEDLINE: 81263210; PMID 6114934]7476558
83. Gardos G, Cole JO, Rapkin RM, LaBrie A, Baquelod E, Moore P, et al. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Archives of General Psychiatry 1984;41(11):1030-5. 7476561
84. Gerlach J, Thorsen K, Fog R. Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia 1975;40(4):341-50. 7476563
85. Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol and biperiden, thioridazine and clozapine. Psychopharmacology 1978;59:105-12. 7476565
86. Bjorndal N, Casey D, Gerlach J. Dopamine antagonist and agonist treatment of tardive dyskinesia. Advances in Biochemical Psychopharmacology 1980;24:541-3. 7476567
87. Gerlach J, Casey DE. Dogmatil in delayed dyskinesia [Le Dogmatil dans les dyskinesies tardives]. Semaine des Hopitaux 1985;61(19):1369-75. 7476568
88. Gerlach J, Casey DE. Sulpiride in tardive dyskinesia. Acta Psychiatrica Scandinavica 1984;69(S311):93-102. 7476569
89. Gerlach J, Korsgaard S, Noring U. Primary (initial) and secondary (tardive) dyskinesia: effect of fluperlapine, a new atypical neuroleptic drug. Catecholamines: Neuropharmacology and Central Nervous System - Therapeutic Aspects. New York: Liss, 1984. 7476571
90. Korsgaard S, Noring U, Gerlach J. Fluperlapine in tardive dyskinesia and parkinsonism. Psychopharmacology 1984;84(1):76-9. 7476572
91. Gibson AC. Depot fluphenazine and tardive dyskinesia in an outpatient population. In: Fann WE, Smith RC, Davis JM, Domino EF editor(s). Tardive Dyskinesia: Research and Treatment. New York: Spectrum Publications, 1980. 7476574
92. Gibson AC. Effect of drug holidays on tardive dyskinesia. In: Usdine E, Forrest IS editor(s). Phenothiazines and structurally related drugs: basic and clinical studies. New York: Elsevier-North Holland, 1980. 7476575
93. Glazer WM, Morre DC, Schooler NR, Brenner LM, Morgenstern H. Tardive dyskinesia: a discontinuation study. Archives of General Psychiatry 1984;41:623-7. 7476577
94. Glazer WM, Bowers MB, Charney DS, Heninger GR. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Biological Psychiatry 1989;26:224-33. 7476579
95. Goldberg SC, Shenoy RS, Sadler A, Hamer R, Ross B. The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics. Psychopharmacology Bulletin 1981;17(1):116-7. [MEDLINE: 81200009; PMID 7232638]7476581
96. Shenoy RS, Sadler AG, Goldberg SC, Hamer RM, Ross B. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology 1981;1(3):141-5. 7476582
97. Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry 1984;145:304-10. [MEDLINE: 85001048; PMID 6148119]7476584
98. Haggstrom J. Sulpride in tardive dyskinesia. Current Therapeutic Research 1980;27(2):164-9. 7476586
99. Heresco-Levy U, Greenberg D, Lerer B, Dasberg H, Brown WA. Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome. Journal of Clinical Psychiatry 1993;54(2):59-62. 7476588
100. Heresco-Levy U, Greenberg D, Lerer B, Dasberg H, Brown WA. Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse. Israel Journal of Psychiatry and Related Science 1995;32(4):268-75. 7476589
101. Hershon HI, Kennedy PF, McGuire RJ. Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. British Journal of Psychiatry 1972;120(554):41-50. 7476591
102. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, et al. Intermittent versus maintenance medication in schizophrenia: two-year results. Archives of General Psychiatiry 1991;48:333-9. 7476593
103. Hogarty GE, Ulrich RF, Mussare F, Aristigueta N. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Diseases of the Nervous System 1976;37:494-500. 7476595
104. Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia - results of a two-year controlled study. Archives of General Psychiatry 1988;45(September):797-805. 7476597
105. Inada T, Beasley CM Jr, Tanaka Y, Walker DJ. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. International Clinical Psychopharmacology. United States of America: Lippincott Williams & Wilkins, 2003; Vol. 18, issue 1:39-48. 7476599
106. Inderbitzin LB, Lewine RRJ, SchellerGilkey G, Swofford CD, Egan GJ, Gloersen BA, et al. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. American Journal of Psychiatry 1994;151(12):1753-9. 7476601
107. Jean-Noel B, Wood AJ, Kiesler GM, Birkett M, Tollefson GD. Olanzapine vs. clozapine: an international double blind study in the treatment of resistant schizophrenia. 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999; Vol. 2:143. 7476603
108. Jeste DV, Olgiati SG, Ghali AY. Masking of tardive dyskinesia with four times-a-day administration of chlorpromazine. Diseases of the Nervous System 1977;38(9):755-8. 7476605
109. Jeste DV, Potkin SG, Sinha S, Feder S, Wyatt RJ. Tardive dyskinesia - reversible and persistent. Archives of General Psychiatry 1979;36(May):585-90. 7476607
110. Johnson DAW, Pasterski G, Ludlow JM, Street K, Taylor RDW. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatrica Scandinavica 1983;67:339-52. 7476609
111. Johnson DA, Ludlow JM, Street K, Taylor RD. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry 1987;151:634-8. 7476611
112. Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ 1989;298(6679):985-90. 7476613
113. Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990;301(6756):837-42. 7476614
114. Jus A, Jus K, Fontaine P. Long term treatment of tardive dyskinesia. Journal of Clinical Psychiatry 1979;40(2):72-7. 7476616
115. Kalachnik JE, Harder SR, Kidd-Nielsen P, Errickson E, Doebler M, Sprague RL. Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction, and no-neuroleptic history groups: preliminary results. Psychopharmacology Bulletin 1984;20(1):27-32. 7476618
116. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia?. Journal of Clinical Psychiatry 1993;54(9):327-30. 7476620
117. Kinon B, Stauffer VL, Wang L, Thi KT, Kollack-Walker S. Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study. International Journal of Neuropsychopharmacology. Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum 2002;5(Suppl 1):S165. 7476622
118. Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Progress in neuro-psychopharmacology & biological psychiatry 2004;28(6):985-96. 7476623
119. Kinon BJ, Stauffer VL, Wang L, Thi K, Niewoehner J, Kollack-Walker S. Olanzapine improves dyskinesia in patients with schizophrenia. International Congress on Schizophrenia Research (ICSR) March 29-April 2, 2003, Colorado Springs, Colorado. 2003. 7476624
120. Kinon BJ, Stauffer VL, Wang L, Thi KT. Olanzapine improves tardive dyskinesia in patients with schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002. 7476625
121. Kinon BJ, Stauffer VL, Wang L, Thi KT. Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophrenia Research 2002;53(3 Suppl.1):191. [MEDLINE: 96173072; PMID 11580001]7476626
122. Kollack-Walker S, Kinon BJ, Stauffer VL, Wang L, Thi KT. Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophrenia Research 2003;60:359. [PsycINFO 2003-06156-011; PMID 12765745]7476627
123. Kirch D, Hattox S, Bell J, Murphy R, Freedman R. Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal. Psychiatry Research 1983;9:217-23. 7476629
124. Kopala L, Rabinowitz J, Emsley R, McGorry P. Extra-pyramidal signs and symptoms (EPS) in recent onset schizophrenia: a comparison of risperidone and haloperidol. Schizophrenia Research 2004;67(1):187. 7476631
125. Lal S, Ettigi P. Comparison of thiopropazate and trifluoperazine on oral dyskinesia - a double blind study. Current Therapeutic Research, Clinical and Experimental 1974;16(9):990-7. 7476633
126. Leblanc G, Cormier H, Gagne MA, Vaillancourt S. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses. Canadian Journal of Psychiatry 1994;39(4):223-9. 7476635
127. Leblhuber F. Treatment of permanent tardive dyskinesia with tiapride, a selective D2-receptor blocking agent. Clinical Neuropharmacology 1987;10(5):458-61. [MEDLINE: 89028406; EMBASE 1989028406; PMID 2902921]7476637
128. Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Advances in Biochemical Psychopharmacology 1980;24:483-93. 7476639
129. Lieberman J, Pollack S, Lesser M, Kane J. Pharmacologic characterization of tardive dyskinesia. Journal of Clinical Psychopharmacology 1988;8(4):254-60. 7476641
130. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry 1991;158:503-10. 7476643
131. Lieberman JA, Saltz BL, Johns CA, Pollack S, Kane, JM. Clozapine effects on tardive dyskinesia. Psychopharmacology Bulletin 1989;25(1):57-62. 7476644
132. Lin CC, Chen JY, Bai YM, Chen TT, Wang YC, Liou YJ, et al. Remission of tardive dyskinesia following the switch from clozapine to zotepine: 2-year follow-up. European Neuropsychopharmacology 2006;16(Suppl 4):S410. 7476646
133. Littrell K, Magill AM. The effect of clozapine - on preexisting tardive dyskinesia. Journal of Psychosocial Nursing and Mental Health Services 1993;31(9):14-8. 7476648
134. MacKay AV, Sheppard GP, Saha BK, Motley B, Johnson A, Marsden CD. Failure of lithium treatment in established tardive dyskinesia. Psychological Medicine 1980;10(3):583-7. 7476650
135. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PRA. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Archives of General Psychiatry 1987;44:518-21. 7476652
136. Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry 1984;41:1025-9. 7476653
137. McCreadie RG, Dingwall JM, Wiles DH, Heykants JJ. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry 1980;137(6):510-7. 7476655
138. Meco G, Bedini L, Bonifati V, Sonsini U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. A single-blind crossover study versus placebo. Current Therapeutic Research - Clinical and Experimental 1989;46(5):876-83. 7476657
139. Miller DD, Flaum M, Arndt S, Fleming F, Andreasen NC. Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology 1994;11(1):11-20. 7476659
140. Gerlach J. Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale 1988;XIV:227-32. 7476661
141. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology 1986;90(4):423-9. 7476662
142. Povlsen UJ, Noring U, Meidahl B, Korsgaard S, Waehrens J, Gerlach J. [Neuroleptikas virkning pa tardive dyskinesier]. Ugeskr Laeger 1987;149(25):1682-5. 7476663
143. Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease. Psychopharmacology Bulletin 1992;28(1):101-7. 7476665
144. Newton JE, Cannon DJ, Couch L, Fody EP, McMillan DE, Metzer WS, et al. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients. Journal of Clinical Psychiatry 1989;50:132-5. 7476667
145. Odejide OA, Aderounmu AF. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry 1982;43:195-6. 7476669
146. Pai Y-M, Yu S-C, Lin C-C. Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002. [NR710 Wednesday, May 9, 3:00 p.m.-5:00 p.m]7476671
147. Pai YM, Yu SC, Lin CC. Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study. Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA. Marathon Multimedia, 2001. [MEDLINE: 96173072; PMID 11580001]7476672
148. Paulson GW, Rizvi CA, Crane GE. Tardive dyskinesia as a possible sequel of long-term therapy with phenothiazines. Clinical Pediatrics 1975;14(10):953-5. 7476674
149. Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacologia 1996;124(1-2):188-96. 7476676
150. Peluso MJ, Lewis SW, Barnes TRE, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. British Journal of Psychiatry 2012;200(5):387-92. 7476678
151. Perry R, Campbell M, Adams P, Lynch N, Spencer EK, Curren EL, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. Journal of the American Academy of Child and Adolescent Psychiatry 1989;28(1):87-92. 7476680
152. Perry R, Campbell M, Green WH, Small AM, Die Trill ML, Meiselas K, et al. Neuroleptic-related dyskinesias in autistic children: a prospective study. Psychopharmacology Bulletin 1985;21(1):140-3. 7476681
153. Pyke J, Seeman M. Neuroleptic-free intervals in the treatment of schizophrenia. American Journal of Psychiatry 1981;138(12):1620-1. 7476683
154. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. Journal of Neurology Neurosurgery and Psychiatry 1984;47(8):844-7. 7476685
155. Quinn N, Marsden, CD. Double blind trial of Dogmatil in Huntington chorea and tardive dyskinesia [Essai en double insu du Dogmatil dans la choree de Huntington et la dyskinesie tardive]. Semaine des Hopitaux 1985;61(19):1376-80. 7476686
156. Quitkin F, Rifkin A, Gochfeld L, Klein DF. Tardive dyskinesia: are first signs reversible?. American Journal of Psychiatry 1977;134:84-7. 7476688
157. Rapoport J, Kumra S, Jacobsen LK. The spectrum of extrapyramidal symptoms in children and young adults. 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA. 1997. [PsycINFO 78-16286]7476690
158. Ringwald E. Dopamine-receptor stimulators and neuroleptic-induced dyskinesia. Pharmakopsychiatrie und Neuropsychopharmakologie 1978;11:294-8. 7476692
159. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290(20):2693-702. 7476694
160. Roxburgh PA. Treatment of persistent phenothiazine-induced oral dyskinesia. British Journal of Psychiatry 1970;116:277-80. 7476696
161. Schultz SK, Miller DD, Arndt S, Ziebell S, Gupta S, Andreasen NC. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Biological Psychiatry 1995;38:713-9. 7476698
162. Schwartz M, Moguillansky L, Lanyi G, Sharf B. Sulpiride in tardive dyskinesia. Journal of Neurology, Neurosurgery & Psychiatry 1990;53(9):800-2. 7476700
163. Seeman MV. Tardive dyskinesia: two-year recovery. Comprehensive Psychiatry 1981;22:189-92. 7476702
164. Simpson GM, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesia. Psychopharmacology 1978;56:75-80. 7476704
165. Singer K, Cheng MN. Thiopropazate hydrochloride (Dartalan) in persistent dyskinesia with phenothiazine therapy. 5th World Congress of Psychiatry; 1971 Nov 28-Dec 4; Ciudad de Mexico, Mexico. 1971:528. [MEDLINE: 79081577; PMID 215095]7476706
166. Singer K, Cheng MN. Thiopropazate hydrochloride in persistent dyskinesia. British Medical Journal 1971;4:22-5. 7476707
167. Singh H, Hunt JI, Vitiello B, Simpson GM. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Journal of Clinical Psychiatry 1990;51:319-21. 7476709
168. Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. Journal of Clinical Psychiatry 1987;48:263-7. 7476711
169. Smith JS, Kiloh LG. Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia. Journal of Neurology, Neurosurgery and Psychiatry 1979;42(6):576-9. 7476713
170. Soni SD, Freeman HL, Hussein EM. Oxypertine in tardive dyskinesia: an 8-week controlled study. British Journal of Psychiatry 1984;144:48-52. [MEDLINE: 84105430; PMID 6140973]7476715
171. Barnes TRE, Speller JC, Curson DA, Pantelis C, Alberts JL. A one-year dose reduction study in chronic schizophrenic inpatients: amisulpride vs haloperidol. Schizophrenia Research 1992;6(2):107. [EMBASE 1997383387]7476717
172. Speller JC, Barnes TRE, Curson DA, Pantelis C, Alberts JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. British Journal of Psychiatry 1997;171(December):564-8. [EMBASE 1997383387]7476718
173. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. Journal of Clinical Psychiatry 1997;58:318-22. 7476720
174. Spohn HE, Coyne L, Spray J. The effect of neuroleptics and tardive dyskinesia on smooth-pursuit eye movement in chronic schizophrenia. Archives of General Psychiatry 1988;45:833-40. 7476722
175. Spohn HE, Coyne L. The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics. Special Issue: tardive dyskinesia and cognitive dysfunction. Brain and Cognition 1993;23(1):28-39. 7476724
176. Suh GH, Son HG, Ju YS, Jcho KH, Yeon BK, Shin Y, et al. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. American Journal of Geriatric Psychiatry 2004;12:509-16. 7476726
177. Thapa PB, Meador KG, Gideon P, Fought RL, Ray WA. Effects of antipsychotic withdrawal in elderly nursing home residents. Journal of the American Geriatrics Society 1994;42:280-6. 7476728
178. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, et al. A randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. British Journal of Psychiatry 1999;174:23-30. 7476730
179. Tamura RN, Tollefson GD, Dellva MA, Beasley CM, Glazer WM, Morgenstern H. What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?. Schizophrenia Research 1998;29:176. 7476731
180. Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry 1997;154:1248-54. 7476732
181. Tran PV, Dellva MA, Tollefson GD, Beasley CMJr, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of clinical psychiatry 1997; Vol. 58, issue 5:205-11. 7476734
182. Turek I, Kurland AA, Hanlon TE, Bohm M. Tardive dyskinesia: its relation to neuroleptic and antiparkinson drugs. British Journal of Psychiatry 1972;121:605-12. 7476736
183. Williamson DJ, Tran PV, Beasley CM, Tollefson GD, Sanger T, Satterlee WG. Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Journal of Psychopharmacology 1995;9:A47. 7476738
184. Wirshing DA, Marshall BD Jr, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. American Journal of Psychiatry 1999;156(9):1374-9. 7476740
185. Wistedt B, Wiles D, Jorgensen A. A depot neuroleptic withdrawal study neurological effects. Psychopharmacology 1983;80:101-5. 7476742
186. Wolf MA, Bailly L, Diener JM, Martinet JP, Peretti S, Garneau Y. [Sevrage neuroleptique complet chez des patients schizophrenes presentant une symptomatologie intense et resistant au traitement]. Encephale 1991;17(4):255-61. 7476744
187. Wright P, Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JII. A blinded, controlled, long-term study of the comparative incidence of treatement-emergent tardive dyskinesia with olanzapine or haloperidol. Schizophrenia Research 1998;29(1-2):206. [No. 84E]7476746
188. Zander KJ, Fischer B, Zimmer R, Ackenheil M. Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal. Psychopharmacology 1981;73:43-7. 7476748
189. Zarebinski JM, Royds JNA. Sulpiride in tardive dyskinesia. South African Medical Journal 1990;78(6):374-5. 7476750
190. Zeng ZX, Li ZC, Yu XW, Zhang YD, Cao ZC. A double-blind trial of flunarizine therapy for tardive dyskinesia. Chinese Journal of Pharmaco Epidemiology 1994;3(4):183-4. 7476752
191. N0546099389. A six month, rater blind comparison of quetiapine and risperidone in the treatment of tardive dyskinesia in patients with schizophrenia. National Research Register (first received 16 July 2015). [N0546099389]7476754
192. Alabed S, Latifeh Y, Mohammad HA, Rifai A. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD000203.pub3]
193. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
194. American Psychiatry Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC, 1992.
195. Armitage P. Should we cross offthe crossover?. Journal of Clinical Pharmacology 1991;32:1-2.
196. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. Journal of Clinical Psychiatry 2008;69(10):1580-8.
197. Ballesteros J, Gonzalez-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. Journal of Clinical Psychopharmacology 2000;20(2):188-94.
198. Barnes TR, Charing C. Westminster Medical School HHES. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672-6.
199. Barnes TRE, Edwards JG. The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects. In: Barnes TRE editor(s). Antipsychotic drugs and their side-effects. London: Academic Press/Harcourt Brace & Company, 1993.
200. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637-9. [PUBMED: 8773637]
201. Bergen JA, Griffiths DA, Rey JM, Beumont PJV. Tardive dyskinesia: fluctuating patient or fluctuating rater. British Journal of Psychiatry 1984;144:498-502.
202. Bergen JA, Eyland EA, Campbell JA. The course of tardive dyskinesia in patients on long-term neuroleptics. British Journal of Psychiatry 1989;154:523-8.
203. Bergin J, Kitchin R, Berry G. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics. Biological Psychiatry 1992;32:580-94.
204. Bergman H, Walker DM, Nikolakopoulou A, Soares-Weiser K, Adams CE. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess 2017 Aug;21(43):1-218.
205. Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD000205.pub2]
206. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
207. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
208. Cadet JL, Lohr JB. Possible involvement of free radical in neuroleptic-induced movement disorders. Annals of the New York Academy of Sciences 1989;570:176-85.
209. Casey D, Gerlach J. Tardive dyskinesia: what is the long-term outcome?. In: Casey D, Gardos G editor(s). Tardive dyskinesia and neuroleptics: from dogma to reason. Washington DC: American Psychiatric Press, 1986.
210. Casey DE. Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994.
211. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophrenia Research 1999;35:S31-S36.
212. Cavallaro R, Regazzetti MG, Mundo E, Brancato V, Smeraldi E. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence. Neuropsychopharmacology 1993;8(3):233-9.
213. Chong SA, Tay JA, Subramaniam M, Pek E, Machin D. Mortality rates among patients with schizophrenia and tardive dyskinesia. Journal of Clinoca; Psychopharmacology 2009;29:5-8.
214. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophrenia Research 2005;76(2-3):247-65.
215. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and Psychosomatics 2008;77(2):69-77.
216. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics 2014;11(1):166-76.
217. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry 2004;161(3):414-25.
218. Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation.
219. Deeks J. Issues in the selection for meta-analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
220. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
221. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
222. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
223. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
224. El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD000458.pub2]
225. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthington HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
226. Essali A, Deirawan H, Soares-Weiser K, Adams CE. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD000206.pub3]
227. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. Journal of Clinical Psychiatry 2000;61(suppl 4):10-14.
228. Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001;56:805-7.
229. Fleiss JL. The crossover study. The Design and Analysis of Clinical Experiments. Chichester: John Wiley & Sons, 1984.
230. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
231. Gardos G, Cole JO, Haskell D, Marby D, Schniebolk Paine S, Moore P. The natural history of tardive dyskinesia. Journal of Clinical Psychopharmacology 1988;8:31S-7S.
232. Gardos G, Casey DE, Cole JO, Perenyi A, Kocsis E, Arato M, et al. Ten-year outcome of tardive dyskinesia. American Journal of Psychiatry 1994;151:836-41.
233. Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatrica Scandinavica 1988;77:369-78.
234. Gerlach J, Korsgaard S, Clemmesen P, Lauersen AML, Magelund G, Noring U, et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatrica Scandinavica 1993;87(4):244-52.
235. Gilbert PL, Harris J, McAdam LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients - a review of the literature. Archives of General Psychiatry 1995;52:173-88.
236. Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. British Journal of Psychiatry 1990;157:585-92.
237. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
238. Guy W, Bonato RR. Manual for the ECDEU Assessment Battery. National Institute of Mental Health. In: Guy W, Bonato RR, editor(s). Washington DC: NIMH, 1970.
239. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised Edition. Washington, DC: Department of Health, Education and Welfare, 1976.
240. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
241. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: Higgins JPT, Green S editor(s). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd., 2005.
242. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
243. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
244. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
245. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
246. Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavanagh DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
247. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophrenia Bulletin 1993;19(2):303-15.
248. Kane JM, Woerner M, Satantakos S, Kinon B, Lieberman J. Do low-dose neuroleptics prevent or ameliorate tardive dyskinesia?. In: Casey D, Gardos G editor(s). Tardive Dyskinesia and Neuroleptics: From Dogma to Reason. Washington DC: American Psychiatric Press, 1986.
249. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
250. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001-5. [PUBMED: 16905632]
251. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
252. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
253. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. Psychological Medicine 2009;39(10):1591-602.
254. Lieberman JA, Fleishhacker W. Introduction. British Journal of Psychiatry 1996;168(Supplement 29):7-8.
255. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 1987;76:Suppl. 334.
256. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. Journal of Managed Care Pharmacy 2012;18(5 Suppl B):S1-20.
257. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 2005;50(9):541-7.
258. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
259. Martins ES, Rosso A, Coutinho E, Adams C, Huf G. Prevalence of tardive dyskinesia and all-cause mortality amongst patients in a large psychiatric institute in Rio de Janeiro. Revista de Psiquiatria Clínica 2011;38:44.
260. Miller DD, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. The Journal of Clinical Psychiatry 2007;68(12):1901-6.
261. Miller DD, CaroffSN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. British Journal of Psychiatry 2008;193(4):279-88.
262. Moher D, Liberati A, TetzlaffJ, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine 6;7:e1000097. [DOI: 10.1371/journal.pmed1000097]
263. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medication. Results of the Yale Tardive Dyskinesia Study. Archives of General Psychiatry 1993;50:723-33.
264. NICE. Psychosis and schizophrenia in adults: treatment and management. NICE clinical guideline 178 (guidance.nice.org.uk/cg178) 2014.
265. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
266. Pocock SJ. Crossover trials. Clinical trials. A practical approach. Chichester: John Wiley & Sons, 1983.
267. Rosenheck RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. British Journal of Psychiatry 2007;191:238-45.
268. Schmidt M, Meister P, Baumann P. Treatment of tardive dyskinesias with vitamin E. European Psychiatry 1991;6:201-7.
269. Schooler NR, Keith SJ. Clinical research for the treatment of schizophrenia. Psychopharmacology Bulletin 1993;29:431-46.
270. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
271. Shale H, Tanner C. Pharmacological options for the management of dyskinesias. Drugs 1996;52(6):849-60.
272. Shokraneh F, Adams CE. Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis. BioImpacts 2017;InPress:InPress.
273. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970;212:11-19.
274. Smith JM, Balessarini RJ. Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry 1980;37:1368-73.
275. Soares K, McGrath J. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000204; MEDLINE: 20257419]
276. Soares-Weiser K, Mobsy C, Holliday E. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 1997, Issue 2. [DOI: 10.1002/14651858.CD000204]
277. Soares-Weiser K, Joy C. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD000208]
278. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD000209.pub2]
279. Tammenmaa I, McGrath J, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD000207; MEDLINE: 22133093]
280. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handbook of Clinical Neurology 2011;100:601-16.
281. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines (10th Edition). London: Informa Healthcare, 2009.
282. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
283. Waddington JL, Crow TJ. Abnormal involuntary movements and psychosis in the preneuroleptic era and in unmedicated patients: implications for the concept of tardive dyskinesia. In: Wolf ME, Mosnaim AD editor(s). Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. Washington DC: American Psychiatric Press, 1988.
284. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. Journal of Clinical Psychiatry 2010;71(4):463-74.
285. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
286. McGrath JJ, Soares-Weiser KVS. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews 1998, Issue 2. [DOI: 10.1002/14651858.CD000459]
287. McGrath J, Soares K. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000459.pub2]
288. Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD000459.pub2]